

Pietro Invernizzi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8742349/publications.pdf>

Version: 2024-02-01

407
papers

26,442
citations

8755

75
h-index

8630

146
g-index

419
all docs

419
docs citations

419
times ranked

25484
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomewide Association Study of Severe Covid-19 with Respiratory Failure. <i>New England Journal of Medicine</i> , 2020, 383, 1522-1534.	27.0	1,548
2	EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. <i>Journal of Hepatology</i> , 2009, 51, 237-267.	3.7	1,540
3	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 557-588.	17.8	1,155
4	Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 261-280.	17.8	964
5	EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , 2017, 67, 145-172.	3.7	889
6	A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. <i>New England Journal of Medicine</i> , 2016, 375, 631-643.	27.0	817
7	Primary biliary cirrhosis in monozygotic and dizygotic twins: Genetics, epigenetics, and environment. <i>Gastroenterology</i> , 2004, 127, 485-492.	1.3	447
8	Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. <i>Nature Genetics</i> , 2010, 42, 658-660.	21.4	389
9	Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. <i>Journal of Hepatology</i> , 2019, 71, 1216-1228.	3.7	388
10	Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study. <i>Gastroenterology</i> , 2014, 147, 1338-1349.e5.	1.3	365
11	Macrophage plasticity and polarization in liver homeostasis and pathology. <i>Hepatology</i> , 2014, 59, 2034-2042.	7.3	359
12	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2017, 152, 1975-1984.e8.	1.3	355
13	Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. <i>Nature Genetics</i> , 2013, 45, 670-675.	21.4	339
14	Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. <i>Gastroenterology</i> , 2015, 149, 1804-1812.e4.	1.3	330
15	Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. <i>Hepatology</i> , 1997, 25, 1090-1095.	7.3	286
16	Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. <i>Hepatology</i> , 2003, 38, 1250-1257.	7.3	281
17	High rates of 30-day mortality in patients with cirrhosis and COVID-19. <i>Journal of Hepatology</i> , 2020, 73, 1063-1071.	3.7	279
18	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. <i>Journal of Hepatology</i> , 2020, 73, 505-515.	3.7	279

#	ARTICLE	IF	CITATIONS
19	The X chromosome and immune associated genes. <i>Journal of Autoimmunity</i> , 2012, 38, J187-J192.	6.5	277
20	Frequency of monosomy X in women with primary biliary cirrhosis. <i>Lancet, The</i> , 2004, 363, 533-535.	13.7	252
21	International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways. <i>Nature Communications</i> , 2015, 6, 8019.	12.8	245
22	Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. <i>Nature Genetics</i> , 2017, 49, 269-273.	21.4	230
23	New functions for an iron storage protein: The role of ferritin in immunity and autoimmunity. <i>Journal of Autoimmunity</i> , 2008, 30, 84-89.	6.5	222
24	Human liver-resident CD56 ^{bright} /CD16 ^{neg} NK cells are retained within hepatic sinusoids via the engagement of CCR5 and CXCR6 pathways. <i>Journal of Autoimmunity</i> , 2016, 66, 40-50.	6.5	220
25	Definition of human autoimmunity "autoantibodies versus autoimmune disease. <i>Autoimmunity Reviews</i> , 2010, 9, A259-A266.	5.8	210
26	Biliary apoptoses and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. <i>Hepatology</i> , 2010, 52, 987-998.	7.3	194
27	Apoptoses and the biliary specificity of primary biliary cirrhosis. <i>Hepatology</i> , 2009, 49, 871-879.	7.3	193
28	Autoimmune liver serology: Current diagnostic and clinical challenges. <i>World Journal of Gastroenterology</i> , 2008, 14, 3374.	3.3	185
29	X Chromosome Monosomy: A Common Mechanism for Autoimmune Diseases. <i>Journal of Immunology</i> , 2005, 175, 575-578.	0.8	180
30	Antinuclear Antibodies in Primary Biliary Cirrhosis. <i>Seminars in Liver Disease</i> , 2005, 25, 298-310.	3.6	173
31	Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. <i>Hepatology</i> , 2006, 43, 1135-1144.	7.3	171
32	Female predominance and X chromosome defects in autoimmune diseases. <i>Journal of Autoimmunity</i> , 2009, 33, 12-16.	6.5	158
33	A sensitive bead assay for antimitochondrial antibodies: Chipping away at AMA-negative primary biliary cirrhosis. <i>Hepatology</i> , 2007, 45, 659-665.	7.3	152
34	Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2001, 34, 366-372.	3.7	150
35	Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. <i>Gut</i> , 2002, 51, 265-269.	12.1	150
36	MicroRNAs in autoimmunity and inflammatory bowel disease: Crucial regulators in immune response. <i>Autoimmunity Reviews</i> , 2012, 11, 305-314.	5.8	150

#	ARTICLE	IF	CITATIONS
37	Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , 2019, 71, 357-365.	3.7	148
38	ImmunoChip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. <i>Human Molecular Genetics</i> , 2012, 21, 5209-5221.	2.9	139
39	Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. <i>Gut</i> , 2016, 65, 321-329.	12.1	139
40	Evolving Trends in Female to Male Incidence and Male Mortality of Primary Biliary Cholangitis. <i>Scientific Reports</i> , 2016, 6, 25906.	3.3	132
41	Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages. <i>Journal of Hepatology</i> , 2017, 66, 102-115.	3.7	130
42	Changing nomenclature for PBC: From "cirrhosis" to "cholangitis". <i>Hepatology</i> , 2015, 62, 1620-1622.	7.3	125
43	Preferential X chromosome loss but random inactivation characterize primary biliary cirrhosis. <i>Hepatology</i> , 2007, 46, 456-462.	7.3	124
44	PBC Screen: An IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , 2010, 35, 436-442.	6.5	123
45	The consequences of apoptosis in autoimmunity. <i>Journal of Autoimmunity</i> , 2008, 31, 257-262.	6.5	122
46	Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies. <i>Oncogene</i> , 2016, 35, 671-682.	5.9	122
47	Human leukocyte antigen polymorphisms in Italian primary biliary cirrhosis: A multicenter study of 664 patients and 1992 healthy controls. <i>Hepatology</i> , 2008, 48, 1906-1912.	7.3	120
48	Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis. <i>Hepatology</i> , 2012, 55, 153-160.	7.3	116
49	Lack of immunological or molecular evidence for a role of mouse mammary tumor retrovirus in primary biliary cirrhosis. <i>Gastroenterology</i> , 2004, 127, 493-501.	1.3	115
50	Iron levels in polarized macrophages: Regulation of immunity and autoimmunity. <i>Autoimmunity Reviews</i> , 2012, 11, 883-889.	5.8	109
51	Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease. <i>Clinical and Experimental Immunology</i> , 2013, 173, 250-258.	2.6	109
52	Estrogen receptors in cholangiocytes and the progression of primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2004, 41, 905-912.	3.7	108
53	Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 626-634.	8.1	103
54	Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism. <i>Gut</i> , 2012, 61, 268-277.	12.1	101

#	ARTICLE	IF	CITATIONS
55	Genetics and Geoeidemiology of Primary Biliary Cirrhosis: Following the Footprints to Disease Etiology. <i>Seminars in Liver Disease</i> , 2005, 25, 265-280.	3.6	100
56	Interpreting Serological Tests in Diagnosing Autoimmune Liver Diseases. <i>Seminars in Liver Disease</i> , 2007, 27, 161-172.	3.6	100
57	Changing Nomenclature for PBC: From "Cirrhosis" to "Cholangitis". <i>Gastroenterology</i> , 2015, 149, 1627-1629.	1.3	96
58	Overexpression of microRNA-21 is associated with elevated pro-inflammatory cytokines in dominant-negative TGF- β 2 receptor type II mouse. <i>Journal of Autoimmunity</i> , 2013, 41, 111-119.	6.5	95
59	Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules. <i>Nature Immunology</i> , 2022, 23, 275-286.	14.5	95
60	Infectome: A platform to trace infectious triggers of autoimmunity. <i>Autoimmunity Reviews</i> , 2013, 12, 726-740.	5.8	94
61	The changing face of chronic autoimmune atrophic gastritis: an updated comprehensive perspective. <i>Autoimmunity Reviews</i> , 2019, 18, 215-222.	5.8	94
62	Y chromosome loss in male patients with primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , 2013, 41, 87-91.	6.5	93
63	A comprehensive evaluation of serum autoantibodies in primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , 2010, 34, 55-58.	6.5	92
64	Autophagy: Highlighting a novel player in the autoimmunity scenario. <i>Journal of Autoimmunity</i> , 2007, 29, 61-68.	6.5	91
65	Serotonin Metabolism Is Dysregulated in Cholangiocarcinoma, which Has Implications for Tumor Growth. <i>Cancer Research</i> , 2008, 68, 9184-9193.	0.9	90
66	The challenges of primary biliary cholangitis: What is new and what needs to be done. <i>Journal of Autoimmunity</i> , 2019, 105, 102328.	6.5	86
67	Vitamin D receptor polymorphisms are associated with increased susceptibility to primary biliary cirrhosis in Japanese and Italian populations. <i>Journal of Hepatology</i> , 2009, 50, 1202-1209.	3.7	85
68	Changing nomenclature for PBC: From "cirrhosis" to "cholangitis". <i>Journal of Hepatology</i> , 2015, 63, 1285-1287.	3.7	85
69	Geoeidemiology of autoimmune liver diseases. <i>Journal of Autoimmunity</i> , 2010, 34, J300-J306.	6.5	83
70	Secretin Stimulates Biliary Cell Proliferation by Regulating Expression of MicroRNA 125b and MicroRNA let7a in Mice. <i>Gastroenterology</i> , 2014, 146, 1795-1808.e12.	1.3	83
71	DNA methylation profiling of the X chromosome reveals an aberrant demethylation on CXCR3 promoter in primary biliary cirrhosis. <i>Clinical Epigenetics</i> , 2015, 7, 61.	4.1	83
72	Role of the stromal-derived factor-1 (SDF-1)"CXCR4 axis in the interaction between hepatic stellate cells and cholangiocarcinoma. <i>Journal of Hepatology</i> , 2012, 57, 813-820.	3.7	82

#	ARTICLE	IF	CITATIONS
73	Understanding short bowel syndrome: Current status and future perspectives. <i>Digestive and Liver Disease</i> , 2020, 52, 253-261.	0.9	82
74	Etiopathogenesis of primary biliary cirrhosis. <i>World Journal of Gastroenterology</i> , 2008, 14, 3328.	3.3	80
75	Clinical Pharmacokinetics of Therapeutic Bile Acids. <i>Clinical Pharmacokinetics</i> , 1996, 30, 333-358.	3.5	79
76	From Bases to Basis: Linking Genetics to Causation in Primary Biliary Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 401-410.	4.4	79
77	The secretin/secretin receptor axis modulates liver fibrosis through changes in transforming growth factor- β 1 biliary secretion in mice. <i>Hepatology</i> , 2016, 64, 865-879.	7.3	79
78	2020 international consensus on ANCA testing beyond systemic vasculitis. <i>Autoimmunity Reviews</i> , 2020, 19, 102618.	5.8	79
79	The genetics of human autoimmune disease. <i>Journal of Autoimmunity</i> , 2009, 33, 290-299.	6.5	78
80	Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine-conjugated species in patients with primary biliary cirrhosis. <i>Hepatology</i> , 1999, 29, 320-327.	7.3	75
81	Peculiar HLA polymorphisms in Italian patients with primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2003, 38, 401-406.	3.7	75
82	Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis. <i>Genes and Immunity</i> , 2012, 13, 461-468.	4.1	75
83	Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. <i>Clinical and Experimental Immunology</i> , 2016, 185, 61-71.	2.6	75
84	Human leukocyte antigen in primary biliary cirrhosis: An old story now reviving. <i>Hepatology</i> , 2011, 54, 714-723.	7.3	74
85	Epigenetic investigation of variably X chromosome inactivated genes in monozygotic female twins discordant for primary biliary cirrhosis. <i>Epigenetics</i> , 2011, 6, 95-102.	2.7	74
86	Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. <i>American Journal of Gastroenterology</i> , 2020, 115, 1066-1074.	0.4	74
87	Autoimmunity and Turner's syndrome. <i>Autoimmunity Reviews</i> , 2012, 11, A538-A543.	5.8	73
88	Th17 and regulatory T lymphocytes in primary biliary cirrhosis and systemic sclerosis as models of autoimmune fibrotic diseases. <i>Autoimmunity Reviews</i> , 2012, 12, 300-304.	5.8	70
89	Overcoming a "Probable" Diagnosis in Antimitochondrial Antibody Negative Primary Biliary Cirrhosis: Study of 100 Sera and Review of the Literature. <i>Clinical Reviews in Allergy and Immunology</i> , 2012, 42, 288-297.	6.5	70
90	Genetic polymorphisms of toll-like receptor 9 influence the immune response to CpG and contribute to hyper-IgM in primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , 2005, 24, 347-352.	6.5	69

#	ARTICLE	IF	CITATIONS
91	Shotgun proteomics: Identification of unique protein profiles of apoptotic bodies from biliary epithelial cells. <i>Hepatology</i> , 2014, 60, 1314-1323.	7.3	68
92	Blood fetal microchimerism in primary biliary cirrhosis. <i>Clinical and Experimental Immunology</i> , 2001, 122, 418-422.	2.6	67
93	Presence of fetal DNA in maternal plasma decades after pregnancy. <i>Human Genetics</i> , 2002, 110, 587-591.	3.8	67
94	Prevalence of primary biliary cirrhosis in adults referring hospital for annual health check-up in Southern China. <i>BMC Gastroenterology</i> , 2010, 10, 100.	2.0	67
95	Substance P increases liver fibrosis by differential changes in senescence of cholangiocytes and hepatic stellate cells. <i>Hepatology</i> , 2017, 66, 528-541.	7.3	67
96	Progress in the Genetics of Primary Biliary Cirrhosis. <i>Seminars in Liver Disease</i> , 2011, 31, 147-156.	3.6	66
97	Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: Molecular networks and biological concepts. <i>Journal of Hepatology</i> , 2015, 62, 198-207.	3.7	66
98	Expert clinical management of autoimmune hepatitis in the real world. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 723-732.	3.7	66
99	Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1127-1136.	3.7	66
100	Epidemiology and Pathogenesis of Primary Biliary Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2004, 38, 264-271.	2.2	65
101	Update on primary biliary cirrhosis. <i>Digestive and Liver Disease</i> , 2010, 42, 401-408.	0.9	65
102	Phenotypical and functional alterations of CD8 regulatory T cells in primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , 2010, 35, 176-180.	6.5	64
103	Increased loss of the Y chromosome in peripheral blood cells in male patients with autoimmune thyroiditis. <i>Journal of Autoimmunity</i> , 2012, 38, J193-J196.	6.5	64
104	The limitations and hidden gems of the epidemiology of primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , 2013, 46, 81-87.	6.5	64
105	Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. <i>American Journal of Gastroenterology</i> , 2018, 113, 254-264.	0.4	64
106	Inhibition of mast cell-secreted histamine decreases biliary proliferation and fibrosis in primary sclerosing cholangitis Mdr2 ^{-/-} mice. <i>Hepatology</i> , 2016, 64, 1202-1216.	7.3	63
107	An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. <i>Journal of Hepatology</i> , 2021, 75, 572-581.	3.7	62
108	Epithelial cell specificity and apoptotic recognition by serum autoantibodies in primary biliary cirrhosis. <i>Hepatology</i> , 2011, 54, 196-203.	7.3	60

#	ARTICLE	IF	CITATIONS
109	Dysregulation of Iron Metabolism in Cholangiocarcinoma Stem-like Cells. <i>Scientific Reports</i> , 2017, 7, 17667.	3.3	60
110	Cholangiocarcinoma in Italy: A national survey on clinical characteristics, diagnostic modalities and treatment. Results from the "Cholangiocarcinoma" committee of the Italian Association for the Study of Liver disease. <i>Digestive and Liver Disease</i> , 2011, 43, 60-65.	0.9	59
111	New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma. <i>Cells</i> , 2020, 9, 688.	4.1	58
112	Genome-Wide Analysis of DNA Methylation, Copy Number Variation, and Gene Expression in Monozygotic Twins Discordant for Primary Biliary Cirrhosis. <i>Frontiers in Immunology</i> , 2014, 5, 128.	4.8	57
113	Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study. <i>Hepatology</i> , 2021, 73, 2099-2109.	7.3	56
114	Antibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody status. <i>Clinical and Experimental Immunology</i> , 1998, 114, 448-454.	2.6	55
115	Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history. <i>Hepatology</i> , 2018, 67, 1920-1930.	7.3	55
116	Coronavirus Disease 2019 in Autoimmune Hepatitis: A Lesson From Immunosuppressed Patients. <i>Hepatology Communications</i> , 2020, 4, 1257-1262.	4.3	55
117	Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multicentre study. <i>Liver International</i> , 2017, 37, 1554-1561.	3.9	54
118	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2076-2084.e2.	4.4	54
119	Geographic Clusters of Primary Biliary Cirrhosis. <i>Clinical and Developmental Immunology</i> , 2003, 10, 127-131.	3.3	53
120	Antimitochondrial Antibodies and Reactivity to N. Aromaticivorans Proteins in Icelandic Patients with Primary Biliary Cirrhosis and Their Relatives. <i>American Journal of Gastroenterology</i> , 2004, 99, 2143-2146.	0.4	53
121	Serum and Biliary Insulin-like Growth Factor I and Vascular Endothelial Growth Factor in Determining the Cause of Obstructive Cholestasis. <i>Annals of Internal Medicine</i> , 2007, 147, 451.	3.9	52
122	Pathway-based analysis of primary biliary cirrhosis genome-wide association studies. <i>Genes and Immunity</i> , 2013, 14, 179-186.	4.1	52
123	Management of patients with autoimmune liver disease during COVID-19 pandemic. <i>Journal of Hepatology</i> , 2020, 73, 453-455.	3.7	51
124	Genetic associations in Italian primary sclerosing cholangitis: Heterogeneity across Europe defines a critical role for HLA-C. <i>Journal of Hepatology</i> , 2010, 52, 712-717.	3.7	50
125	Lack of Siglec-7 expression identifies a dysfunctional natural killer cell subset associated with liver inflammation and fibrosis in chronic HCV infection. <i>Gut</i> , 2016, 65, 1998-2006.	12.1	50
126	Blocking H1/H2 histamine receptors inhibits damage/fibrosis in Mdr2 ^{-/-} mice and human cholangiocarcinoma tumorigenesis. <i>Hepatology</i> , 2018, 68, 1042-1056.	7.3	50

#	ARTICLE	IF	CITATIONS
127	Multi-Teaching Styles Approach and Active Reflection: Effectiveness in Improving Fitness Level, Motor Competence, Enjoyment, Amount of Physical Activity, and Effects on the Perception of Physical Education Lessons in Primary School Children. <i>Sustainability</i> , 2019, 11, 405.	3.2	49
128	X Monosomy in Female Systemic Lupus Erythematosus. <i>Annals of the New York Academy of Sciences</i> , 2007, 1110, 84-91.	3.8	48
129	Future directions in genetic for autoimmune diseases. <i>Journal of Autoimmunity</i> , 2009, 33, 1-2.	6.5	48
130	Experimental evidence on the immunopathogenesis of primary biliary cirrhosis. <i>Cellular and Molecular Immunology</i> , 2010, 7, 1-10.	10.5	47
131	Knockout of microRNA-21 reduces biliary hyperplasia and liver fibrosis in cholestatic bile duct ligated mice. <i>Laboratory Investigation</i> , 2016, 96, 1256-1267.	3.7	47
132	Dexamethasone Conjugation to Biodegradable Avidin-Nucleic-Acid-Nano-Assemblies Promotes Selective Liver Targeting and Improves Therapeutic Efficacy in an Autoimmune Hepatitis Murine Model. <i>ACS Nano</i> , 2019, 13, 4410-4423.	14.6	47
133	Increased local dopamine secretion has growth-promoting effects in cholangiocarcinoma. <i>International Journal of Cancer</i> , 2010, 126, 2112-2122.	5.1	46
134	Melatonin exerts by an autocrine loop antiproliferative effects in cholangiocarcinoma; its synthesis is reduced favoring cholangiocarcinoma growth. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 301, G623-G633.	3.4	46
135	Vitamin D in autoimmune liver disease. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2013, 37, 535-545.	1.5	45
136	Prolonged darkness reduces liver fibrosis in a mouse model of primary sclerosing cholangitis by miR-200b down-regulation. <i>FASEB Journal</i> , 2017, 31, 4305-4324.	0.5	45
137	Keratin variants are overrepresented in primary biliary cirrhosis and associate with disease severity. <i>Hepatology</i> , 2009, 50, 546-554.	7.3	44
138	Liver auto-immunology: The paradox of autoimmunity in a tolerogenic organ. <i>Journal of Autoimmunity</i> , 2013, 46, 1-6.	6.5	44
139	Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15years. <i>Autoimmunity Reviews</i> , 2016, 15, 162-166.	5.8	44
140	Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. <i>Digestive Diseases and Sciences</i> , 1996, 41, 809-815.	2.3	43
141	Genetic polymorphisms influencing xenobiotic metabolism and transport in patients with primary biliary cirrhosis. <i>Hepatology</i> , 2005, 41, 55-63.	7.3	43
142	Forkhead box A2 regulates biliary heterogeneity and senescence during cholestatic liver injury in mice. <i>Hepatology</i> , 2017, 65, 544-559.	7.3	43
143	Clinical treatment of cholangiocarcinoma: an updated comprehensive review. <i>Annals of Hepatology</i> , 2022, 27, 100737.	1.5	43
144	Genetics and Epigenetics of Primary Biliary Cirrhosis. <i>Seminars in Liver Disease</i> , 2014, 34, 255-264.	3.6	42

#	ARTICLE	IF	CITATIONS
145	Dermatological Complications After Solid Organ Transplantation. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 54, 185-212.	6.5	42
146	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. <i>Gut</i> , 2018, 67, 1517-1524.	12.1	42
147	Primary biliary cirrhosis: does X mark the spot?. <i>Autoimmunity Reviews</i> , 2004, 3, 493-499.	5.8	41
148	Skewing of X chromosome inactivation in autoimmunity. <i>Autoimmunity</i> , 2008, 41, 272-277.	2.6	41
149	Inhibition of the apelin/apelin receptor axis decreases cholangiocarcinoma growth. <i>Cancer Letters</i> , 2017, 386, 179-188.	7.2	41
150	Clinical features and management of primary biliary cirrhosis. <i>World Journal of Gastroenterology</i> , 2008, 14, 3313.	3.3	41
151	Gene dosage as a relevant mechanism contributing to the determination of ovarian function in Turner syndrome. <i>Human Reproduction</i> , 2014, 29, 368-379.	0.9	39
152	A functional characteristic of cysteine-rich protein 61: Modulation of myeloid-derived suppressor cells in liver inflammation. <i>Hepatology</i> , 2018, 67, 232-246.	7.3	39
153	Acute liver and renal failure during treatment with buprenorphine at therapeutic dose. <i>Digestive and Liver Disease</i> , 2009, 41, e8-e10.	0.9	38
154	Identification of New Autoantigens by Protein Array Indicates a Role for IL4 Neutralization in Autoimmune Hepatitis. <i>Molecular and Cellular Proteomics</i> , 2012, 11, 1885-1897.	3.8	38
155	Towards common denominators in primary biliary cirrhosis: The role of IL-12. <i>Journal of Hepatology</i> , 2012, 56, 731-733.	3.7	38
156	Sex Differences Associated with Primary Biliary Cirrhosis. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-11.	3.3	37
157	Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1138-1146.	3.7	37
158	Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in tauro lithocholic acid-induced cholestasis in rat liver. <i>Hepatology</i> , 2010, 52, 1758-1768.	7.3	36
159	Changing nomenclature for PBC: From "cirrhosis" to "cholangitis". <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, e57-e59.	1.5	36
160	Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 1427-1434.	3.7	35
161	Genes and (auto)immunity in primary biliary cirrhosis. <i>Genes and Immunity</i> , 2005, 6, 543-556.	4.1	35
162	Comparative analysis of portal cell infiltrates in antimitochondrial autoantibody-positive versus antimitochondrial autoantibody-negative primary biliary cirrhosis. <i>Hepatology</i> , 2012, 55, 1495-1506.	7.3	35

#	ARTICLE	IF	CITATIONS
163	Tracing environmental markers of autoimmunity: introducing the infectome. <i>Immunologic Research</i> , 2013, 56, 220-240.	2.9	35
164	NIâ€0801, an antiâ€chemokine (Câ€Xâ€C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid. <i>Hepatology Communications</i> , 2018, 2, 492-503.	4.3	35
165	Endoscopic Findings in Patients Infected With 2019 Novel Coronavirus in Lombardy, Italy. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2375-2377.	4.4	35
166	Implications of genomeâ€wide association studies in novel therapeutics in primary biliary cirrhosis. <i>European Journal of Immunology</i> , 2014, 44, 945-954.	2.9	34
167	The critical role of myeloid-derived suppressor cells and FXR activation in immune-mediated liver injury. <i>Journal of Autoimmunity</i> , 2014, 53, 55-66.	6.5	34
168	Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4557.	4.1	34
169	Effect of Anti-Carbonic Anhydrase Antibodies on Carbonic Anhydrases I and II. <i>Clinical Chemistry</i> , 2003, 49, 1221-1223.	3.2	33
170	The fingerprint of antimitochondrial antibodies and the etiology of primary biliary cholangitis. <i>Hepatology</i> , 2017, 65, 1670-1682.	7.3	33
171	Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) â‰2 cm: Study Protocol for a Prospective Observational Study. <i>Frontiers in Medicine</i> , 2020, 7, 598438.	2.6	33
172	Real-world experience with obeticholic acid in patients with primary biliary cholangitis. <i>JHEP Reports</i> , 2021, 3, 100248.	4.9	33
173	Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. <i>Journal of Hepatology</i> , 2022, 77, 1545-1553.	3.7	33
174	Geoeidemiology, Genetic and Environmental Risk Factors for PBC. <i>Digestive Diseases</i> , 2015, 33, 94-101.	1.9	32
175	Novel therapeutics for primary biliary cholangitis: Toward a disease-stage-based approach. <i>Autoimmunity Reviews</i> , 2016, 15, 870-876.	5.8	32
176	AISF position paper on liver disease and pregnancy. <i>Digestive and Liver Disease</i> , 2016, 48, 120-137.	0.9	32
177	Secretin/secretin receptor signaling mediates biliary damage and liver fibrosis in earlyâ€stage primary biliary cholangitis. <i>FASEB Journal</i> , 2019, 33, 10269-10279.	0.5	32
178	Amelioration of Ductular Reaction by Stem Cell Derived Extracellular Vesicles in MDR2 Knockout Mice via Lethalâ€7 microRNA. <i>Hepatology</i> , 2019, 69, 2562-2578.	7.3	32
179	Replicated association of 17q12â€21 with susceptibility of primary biliary cirrhosis in a Japanese cohort. <i>Tissue Antigens</i> , 2011, 78, 65-68.	1.0	31
180	Advances in pharmacotherapy for primary biliary cirrhosis. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 633-643.	1.8	31

#	ARTICLE	IF	CITATIONS
181	SNP Analysis of Genes Implicated in T Cell Proliferation in Primary Biliary Cirrhosis. <i>Clinical and Developmental Immunology</i> , 2005, 12, 259-263.	3.3	30
182	Quality of life and everyday activities in patients with primary biliary cirrhosis. <i>Hepatology</i> , 2007, 46, 1836-1843.	7.3	30
183	The X Chromosome in Female-Predominant Autoimmune Diseases. <i>Annals of the New York Academy of Sciences</i> , 2007, 1110, 57-64.	3.8	30
184	Changing Nomenclature for PBC: From "Cirrhosis" to "Cholangitis". <i>American Journal of Gastroenterology</i> , 2015, 110, 1536-1538.	0.4	30
185	Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1688-1697.e14.	4.4	30
186	Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis: a pilot crossover study. <i>Alimentary Pharmacology and Therapeutics</i> , 1997, 11, 409-414.	3.7	29
187	miR-24 Inhibition Increases Menin Expression and Decreases Cholangiocarcinoma Proliferation. <i>American Journal of Pathology</i> , 2017, 187, 570-580.	3.8	29
188	Support of precision medicine through risk-stratification in autoimmune liver diseases " histology, scoring systems, and non-invasive markers. <i>Autoimmunity Reviews</i> , 2018, 17, 854-865.	5.8	29
189	Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2 ^{-/-} mice and human primary sclerosing cholangitis. <i>Laboratory Investigation</i> , 2018, 98, 1465-1477.	3.7	29
190	DCLK1, a Putative Stem Cell Marker in Human Cholangiocarcinoma. <i>Hepatology</i> , 2021, 73, 144-159.	7.3	29
191	Genes and goals: An approach to microarray analysis in autoimmunity. <i>Autoimmunity Reviews</i> , 2005, 4, 414-422.	5.8	28
192	Changing nomenclature for PBC: from "cirrhosis" to "cholangitis". <i>Gut</i> , 2015, 64, 1671-1672.	12.1	28
193	Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 483-494.	2.5	28
194	Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. <i>Gut</i> , 2020, 69, 1502-1509.	12.1	28
195	Accuracy of Transient Elastography in Assessing Fibrosis at Diagnosis in Naïve Patients With Primary Biliary Cholangitis: A Dual Cut-Off Approach. <i>Hepatology</i> , 2021, 74, 1496-1508.	7.3	28
196	544 Prognostic value of autoantibodies against proteins of nuclear pore complexes (anti-NPCS) in early primary biliary cirrhosis (PBC). <i>Journal of Hepatology</i> , 2004, 40, 159-160.	3.7	27
197	Bovine fetal microchimerism in normal and embryo transfer pregnancies and its implications for biotechnology applications in cattle. <i>Biotechnology Journal</i> , 2007, 2, 486-491.	3.5	27
198	Neuropeptide Y inhibits cholangiocarcinoma cell growth and invasion. <i>American Journal of Physiology - Cell Physiology</i> , 2011, 300, C1078-C1089.	4.6	27

#	ARTICLE	IF	CITATIONS
199	Skin Manifestations Associated with Autoimmune Liver Diseases: a Systematic Review. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 53, 394-412.	6.5	27
200	X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis. <i>Gastroenterology</i> , 2021, 160, 2483-2495.e26.	1.3	27
201	A short version of a HRQoL questionnaire for Italian and Japanese patients with Primary Biliary Cirrhosis. <i>Digestive and Liver Disease</i> , 2010, 42, 718-723.	0.9	26
202	The overlap syndrome between primary biliary cirrhosis and primary sclerosing cholangitis. <i>Digestive and Liver Disease</i> , 2015, 47, 432-435.	0.9	26
203	The epigenetics of PBC: The link between genetic susceptibility and environment. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 650-659.	1.5	26
204	Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies. <i>World Journal of Gastroenterology</i> , 2021, 27, 5890-5907.	3.3	26
205	Autoimmune liver diseases. <i>World Journal of Gastroenterology</i> , 2008, 14, 3290.	3.3	26
206	Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis. <i>Liver International</i> , 2022, 42, 607-614.	3.9	26
207	Immunopathogenesis of primary biliary cirrhosis: an old wives' tale. <i>Immunity and Ageing</i> , 2011, 8, 12.	4.2	25
208	Downregulation of hepatic stem cell factor by Vivo-Morpholino treatment inhibits mast cell migration and decreases biliary damage/senescence and liver fibrosis in Mdr2 ^{-/-} mice. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 165557.	3.8	25
209	Experimental models to unravel the molecular pathogenesis, cell of origin and stem cell properties of cholangiocarcinoma. <i>Liver International</i> , 2019, 39, 79-97.	3.9	25
210	The X chromosome and systemic sclerosis. <i>Current Opinion in Rheumatology</i> , 2006, 18, 601-605.	4.3	24
211	Autoimmune hepatitis type 2 associated with an unexpected and transient presence of primary biliary cirrhosis-specific antimitochondrial antibodies: a case study and review of the literature. <i>BMC Gastroenterology</i> , 2012, 12, 92.	2.0	24
212	Apoptosis and innate immune system: Novel players in the primary biliary cirrhosis scenario. <i>Digestive and Liver Disease</i> , 2013, 45, 630-636.	0.9	24
213	The immunobiology of female predominance in primary biliary cholangitis. <i>Journal of Autoimmunity</i> , 2018, 95, 124-132.	6.5	24
214	Tamoxifen in treatment of primary biliary cirrhosis. <i>Hepatology</i> , 2004, 39, 1175-1176.	7.3	23
215	Characterization of Autoantibodies against Components of the Nuclear Pore Complexes: High Frequency of Anti-p62 Nucleoporin Antibodies. <i>Annals of the New York Academy of Sciences</i> , 2007, 1109, 519-530.	3.8	23
216	Serum autoantibodies: A road map for the clinical hepatologist. <i>Autoimmunity</i> , 2008, 41, 27-34.	2.6	23

#	ARTICLE	IF	CITATIONS
217	Effect of L-Acetylcarnitine on Body Composition in HIV-related Lipodystrophy. <i>Hormone and Metabolic Research</i> , 2009, 41, 840-845.	1.5	23
218	Identification of Circulating MicroRNAs in Biliary Atresia by Next-Generation Sequencing. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2016, 63, 518-523.	1.8	23
219	Primary Biliary Cholangitis: advances in management and treatment of the disease. <i>Digestive and Liver Disease</i> , 2017, 49, 841-846.	0.9	23
220	Modulation of the Tryptophan Hydroxylase 1/Monoamine Oxidase A/5-Hydroxytryptamine/5-Hydroxytryptamine Receptor 2A/2B/2C Axis Regulates Biliary Proliferation and Liver Fibrosis During Cholestasis. <i>Hepatology</i> , 2020, 71, 990-1008.	7.3	23
221	Quantitation of the Rank-Rankl Axis in Primary Biliary Cholangitis. <i>PLoS ONE</i> , 2016, 11, e0159612.	2.5	23
222	Therapeutic Potential of IL-17-Mediated Signaling Pathway in Autoimmune Liver Diseases. <i>Mediators of Inflammation</i> , 2015, 2015, 1-12.	3.0	22
223	Making Sense of Autoantibodies in Cholestatic Liver Diseases. <i>Clinics in Liver Disease</i> , 2016, 20, 33-46.	2.1	22
224	Prognostic models in primary biliary cholangitis. <i>Journal of Autoimmunity</i> , 2018, 95, 171-178.	6.5	22
225	Immune system and cholangiocytes: A puzzling affair in primary biliary cholangitis. <i>Journal of Leukocyte Biology</i> , 2020, 108, 659-671.	3.3	22
226	Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis. <i>Liver International</i> , 2020, 40, 1408-1414.	3.9	22
227	New Therapeutic Targets in Autoimmune Cholangiopathies. <i>Frontiers in Medicine</i> , 2020, 7, 117.	2.6	22
228	The Genetic Basis of Primary Biliary Cirrhosis: Premises, Not Promises. <i>Gastroenterology</i> , 2008, 135, 1044-1047.	1.3	21
229	Genetic association of Fc receptor-like 3 polymorphisms with susceptibility to primary biliary cirrhosis: ethnic comparative study in Japanese and Italian patients. <i>Tissue Antigens</i> , 2011, 77, 239-243.	1.0	21
230	Clinical and prognostic implications of acute onset of Autoimmune Hepatitis: An Italian multicentre study. <i>Digestive and Liver Disease</i> , 2018, 50, 698-702.	0.9	21
231	Antidiabetic thiazolidinediones induce ductal differentiation but not apoptosis in pancreatic cancer cells. <i>World Journal of Gastroenterology</i> , 2005, 11, 1122.	3.3	21
232	Genetic variants of endothelial nitric oxide synthase in patients with primary biliary cirrhosis: Association with disease severity. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003, 18, 1150-1155.	2.8	20
233	Peak inflammation in atherosclerosis, primary biliary cirrhosis and autoimmune arthritis is counter-intuitively associated with regulatory T cell enrichment. <i>Immunobiology</i> , 2015, 220, 1025-1029.	1.9	20
234	Elevated circulating CD14 ^{low} CD16 ⁺ monocyte subset in primary biliary cirrhosis correlates with liver injury and promotes Th1 polarization. <i>Clinical and Experimental Medicine</i> , 2016, 16, 511-521.	3.6	19

#	ARTICLE	IF	CITATIONS
235	â€˜It's as if PBC didn't existâ€™: The illness experience of women affected by primary biliary cirrhosis. <i>Psychology and Health</i> , 2011, 26, 1429-1445.	2.2	18
236	GS-02-Efficacy of GKT831 in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid: Interim efficacy results of a phase 2 clinical trial. <i>Journal of Hepatology</i> , 2019, 70, e1-e2.	3.7	18
237	Pinelectomy or light exposure exacerbates biliary damage and liver fibrosis in cholestatic rats through decreased melatonin synthesis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 1525-1539.	3.8	18
238	The genetic architecture of primary biliary cholangitis. <i>European Journal of Medical Genetics</i> , 2021, 64, 104292.	1.3	18
239	Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CTâ€P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study. <i>Clinical and Translational Science</i> , 2022, 15, 172-181.	3.1	18
240	E. coli and the etiology of human PBC: Antimitochondrial antibodies and spreading determinants. <i>Hepatology</i> , 2022, 75, 266-279.	7.3	18
241	Systematic reviewâ€”pancreatic involvement in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1478-1491.	3.7	18
242	The Role of Macrophages in Liver Fibrosis: New Therapeutic Opportunities. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6649.	4.1	18
243	The cumulative effects of known susceptibility variants to predict primary biliary cirrhosis risk. <i>Genes and Immunity</i> , 2015, 16, 193-198.	4.1	17
244	Nicotine Promotes Cholangiocarcinoma Growth in Xenograft Mice. <i>American Journal of Pathology</i> , 2017, 187, 1093-1105.	3.8	17
245	Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma. <i>American Journal of Pathology</i> , 2019, 189, 2090-2101.	3.8	17
246	Iron Metabolism in Liver Cancer Stem Cells. <i>Frontiers in Oncology</i> , 2019, 9, 149.	2.8	17
247	Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 684-692.e6.	4.4	17
248	Response and relapse rates after treatment with long-acting somatostatin analogs in multifocal or recurrent typeâ€1 gastric carcinoids: A systematic review and meta-analysis. <i>United European Gastroenterology Journal</i> , 2020, 8, 140-147.	3.8	17
249	Primary Sclerosing Cholangitis: Burden of Disease and Mortality Using Data from the National Rare Diseases Registry in Italy. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 3095.	2.6	17
250	The Enigma of Primary Biliary Cirrhosis. <i>Clinical Reviews in Allergy and Immunology</i> , 2005, 28, 073-082.	6.5	16
251	Changing Nomenclature for PBC: From â€˜Cirrhosisâ€™ to â€˜Cholangitisâ€™. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1867-1869.	4.4	16
252	Autonomic modulations of heart rate variability and performances in short-distance elite swimmers. <i>European Journal of Applied Physiology</i> , 2015, 115, 825-835.	2.5	16

#	ARTICLE	IF	CITATIONS
253	Rectal neuroendocrine tumors: Current advances in management, treatment, and surveillance. <i>World Journal of Gastroenterology</i> , 2022, 28, 1123-1138.	3.3	16
254	Methylation and liver cancer. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2013, 37, 564-571.	1.5	15
255	Changing nomenclature for PBC: From "cirrhosis" to "cholangitis". <i>Digestive and Liver Disease</i> , 2015, 47, 924-926.	0.9	15
256	Inhibition of microRNA-24 increases liver fibrosis by enhanced menin expression in Mdr2 $\hat{\wedge}$ / $\hat{\wedge}$ mice. <i>Journal of Surgical Research</i> , 2017, 217, 160-169.	1.6	15
257	Primary biliary cholangitis management: controversies, perspectives and daily practice implications from an expert panel. <i>Liver International</i> , 2020, 40, 2590-2601.	3.9	15
258	Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis. <i>Liver International</i> , 2020, 40, 1121-1129.	3.9	15
259	The protease inhibitor SerpinB3 as a critical modulator of the stemlike subset in human cholangiocarcinoma. <i>Liver International</i> , 2022, 42, 233-248.	3.9	15
260	Primary Biliary Cholangitis Associated with Skin Disorders: A Case Report and Review of the Literature. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2017, 65, 299-309.	2.3	14
261	Knockdown of Hepatic Gonadotropin-Releasing Hormone by Vivo-Morpholino Decreases Liver Fibrosis in Multidrug Resistance Gene 2 Knockout Mice by Down-Regulation of miR-200b. <i>American Journal of Pathology</i> , 2017, 187, 1551-1565.	3.8	14
262	Knockout of $\hat{\pm}$ -calcitonin gene-related peptide attenuates cholestatic liver injury by differentially regulating cellular senescence of hepatic stellate cells and cholangiocytes. <i>Laboratory Investigation</i> , 2019, 99, 764-776.	3.7	14
263	CXCR7 contributes to the aggressive phenotype of cholangiocarcinoma cells. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 2246-2256.	3.8	14
264	Gastro-entero-pancreatic neuroendocrine neoplasia: The rules for non-operative management. <i>Surgical Oncology</i> , 2020, 35, 141-148.	1.6	14
265	Primary biliary cholangitis: a multifaceted pathogenesis with potential therapeutic targets. <i>Journal of Hepatology</i> , 2020, 73, 965-966.	3.7	14
266	Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists. <i>Diseases (Basel, Switzerland)</i> , 2020, 8, 20.	2.5	14
267	Characterization of the antibodies to p62 nucleoprotein in primary biliary cirrhosis using human recombinant antigen. <i>Journal of Cellular Biochemistry</i> , 2008, 104, 27-37.	2.6	13
268	Impaired indoleamine 2,3-dioxygenase production contributes to the development of autoimmunity in primary biliary cirrhosis. <i>Autoimmunity</i> , 2008, 41, 92-99.	2.6	13
269	Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies. <i>Annals of Hepatology</i> , 2020, 19, 5-16.	1.5	13
270	Multifaceted Aspects of Metabolic Plasticity in Human Cholangiocarcinoma: An Overview of Current Perspectives. <i>Cells</i> , 2020, 9, 596.	4.1	13

#	ARTICLE	IF	CITATIONS
271	Risk of preoperative understaging of duodenal neuroendocrine neoplasms: a plea for caution in the treatment strategy. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 2227-2234.	3.3	13
272	The application of artificial intelligence in hepatology: A systematic review. <i>Digestive and Liver Disease</i> , 2022, 54, 299-308.	0.9	13
273	Acute mesenteric ischemia and small bowel imaging findings in COVID-19: A comprehensive review of the literature. <i>World Journal of Gastrointestinal Surgery</i> , 2021, 13, 702-716.	1.5	13
274	Endoscopic techniques for diagnosis and treatment of gastro-entero-pancreatic neuroendocrine neoplasms: Where we are. <i>World Journal of Gastroenterology</i> , 2022, 28, 3258-3273.	3.3	13
275	Primary Biliary Cirrhosis: Solving the Enigma. <i>Annals of the New York Academy of Sciences</i> , 2005, 1051, 185-193.	3.8	12
276	Fetal Microchimerism in Normal and Embryo Transfer Bovine Pregnancies. <i>Veterinary Research Communications</i> , 2007, 31, 205-207.	1.6	12
277	TNF Polymorphisms in Primary Biliary Cirrhosis: A Northern and Southern Italian Experience. <i>Annals of the New York Academy of Sciences</i> , 2009, 1173, 557-563.	3.8	12
278	Human cholangiocarcinoma development is associated with dysregulation of opioidergic modulation of cholangiocyte growth. <i>Digestive and Liver Disease</i> , 2009, 41, 523-533.	0.9	12
279	Toward precision medicine in primary biliary cholangitis. <i>Digestive and Liver Disease</i> , 2016, 48, 843-850.	0.9	12
280	From pathogenesis to novel therapies in the treatment of primary biliary cholangitis. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 1121-1131.	3.0	12
281	Comprehensive review of autoantibodies in patients with hyper-IgM syndrome. <i>Cellular and Molecular Immunology</i> , 2018, 15, 610-617.	10.5	12
282	Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 54, 295-306.	6.5	12
283	Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study. <i>Digestive and Liver Disease</i> , 2020, 52, 190-198.	0.9	12
284	Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study. <i>Digestive and Liver Disease</i> , 2021, 53, 367-374.	0.9	12
285	Impact of the new definition of metabolic dysfunction-associated fatty liver disease on detection of significant liver fibrosis in US adolescents. <i>Hepatology Communications</i> , 2022, 6, 2070-2078.	4.3	12
286	Telomere dysfunction in peripheral blood mononuclear cells from patients with primary biliary cirrhosis. <i>Digestive and Liver Disease</i> , 2014, 46, 363-368.	0.9	11
287	“œœ Miss My Liver.” Nonmedical Sources in the History of Hepatocentrism. <i>Hepatology Communications</i> , 2018, 2, 986-993.	4.3	11
288	A National Hospital-Based Study of Hospitalized Patients With Primary Biliary Cholangitis. <i>Hepatology Communications</i> , 2019, 3, 1250-1257.	4.3	11

#	ARTICLE	IF	CITATIONS
289	The Role of Epigenetics in Primary Biliary Cholangitis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4873.	4.1	11
290	Novel biomarkers for primary biliary cholangitis to improve diagnosis and understand underlying regulatory mechanisms. <i>Liver International</i> , 2019, 39, 2124-2135.	3.9	10
291	Impact of COVID-19 on inflammatory bowel disease practice and perspectives for the future. <i>World Journal of Gastroenterology</i> , 2021, 27, 5520-5535.	3.3	10
292	The "gut microbiota" hypothesis in primary sclerosing cholangitis. <i>Annals of Translational Medicine</i> , 2016, 4, 512-512.	1.7	10
293	Precision medicine in primary biliary cholangitis. <i>Journal of Digestive Diseases</i> , 2019, 20, 338-345.	1.5	9
294	Hepatic focal nodular hyperplasia after pediatric hematopoietic stem cell transplantation: The impact of hormonal replacement therapy and iron overload. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28137.	1.5	9
295	Presence of fetal DNA in maternal plasma decades after pregnancy: further comments. <i>Human Genetics</i> , 2002, 111, 576-576.	3.8	8
296	Towards systemic sclerosis and away from primary biliary cirrhosis: the case of PTPN22. <i>Autoimmunity Highlights</i> , 2012, 3, 1-9.	3.9	8
297	New therapeutics in primary biliary cirrhosis: will there ever be light?. <i>Liver International</i> , 2014, 34, 167-170.	3.9	8
298	Geoeconomics and (epi-)genetics in primary biliary cholangitis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 34-35, 11-15.	2.4	8
299	Study of the influence of heme oxygenase 1 gene single nucleotide polymorphism (rs2071746) on esophageal varices among patients with cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 888-892.	1.6	8
300	COVID-19 in Patients With Inflammatory Bowel Disease: A Single-center Observational Study in Northern Italy. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e138-e139.	1.9	8
301	Intratumor Microbiome in Neuroendocrine Neoplasms: A New Partner of Tumor Microenvironment? A Pilot Study. <i>Cells</i> , 2022, 11, 692.	4.1	8
302	Decreased Serum Leptin Levels in Primary Biliary Cirrhosis: A Link between Metabolism and Autoimmunity?. <i>Annals of the New York Academy of Sciences</i> , 2005, 1051, 211-217.	3.8	7
303	Drug-induced liver injury: Is it time for genetics to change our clinical practice?. <i>Journal of Hepatology</i> , 2010, 53, 993-994.	3.7	7
304	Interpretation and Perception of Slow, Moderate, and Fast Swimming Paces in Distance and Sprint Swimmers. <i>Perceptual and Motor Skills</i> , 2014, 118, 833-849.	1.3	7
305	Ursodeoxycholic acid treatment is associated with prolonged transplant-free survival in primary biliary cholangitis " even in patients without biochemical improvements. <i>Journal of Hepatology</i> , 2018, 68, S8.	3.7	7
306	Quality of life in patients with primary biliary cholangitis: A cross-geographical comparison. <i>Journal of Translational Autoimmunity</i> , 2021, 4, 100081.	4.0	7

#	ARTICLE	IF	CITATIONS
307	MEDTEC Students against Coronavirus: Investigating the Role of Hemostatic Genes in the Predisposition to COVID-19 Severity. <i>Journal of Personalized Medicine</i> , 2021, 11, 1166.	2.5	7
308	Machine learning in primary biliary cholangitis: A novel approach for risk stratification. <i>Liver International</i> , 2022, 42, 615-627.	3.9	7
309	Primary Biliary Cirrhosis: Bad Genes, Bad Luck. <i>Digestive Diseases and Sciences</i> , 2012, 57, 599-601.	2.3	6
310	Primary Biliary Cirrhosis. <i>Seminars in Liver Disease</i> , 2014, 34, 253-254.	3.6	6
311	Autoantibodies in patients with interleukin 12 receptor beta 1 deficiency. <i>Journal of Digestive Diseases</i> , 2019, 20, 363-370.	1.5	6
312	Free episomal and integrated HBV DNA in HBsAg-negative patients with intrahepatic cholangiocarcinoma. <i>Oncotarget</i> , 2019, 10, 3931-3938.	1.8	6
313	Soluble CD40L in Plasma of Patients with Primary Biliary Cirrhosis. <i>Annals of the New York Academy of Sciences</i> , 2005, 1051, 205-210.	3.8	5
314	Intrahepatic cholestasis of pregnancy: A further important step in dissecting its genetic architecture. <i>Digestive and Liver Disease</i> , 2013, 45, 266-267.	0.9	5
315	Interpretation and Perception of Two Different Kumite Fighting Intensities through an Integrated Approach Training in International Level Karatekas: An Exploratory Study. <i>Perceptual and Motor Skills</i> , 2015, 121, 333-349.	1.3	5
316	Better end points needed in primary sclerosing cholangitis trials. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 143-144.	17.8	5
317	Glycomic analysis of antibody indicates distinctive glycosylation profile in patients with autoimmune cholangitis. <i>Journal of Autoimmunity</i> , 2020, 113, 102503.	6.5	5
318	Case Report: Hypomorphic Function and Somatic Reversion in DOCK8 Deficiency in One Patient With Two Novel Variants and Sclerosing Cholangitis. <i>Frontiers in Immunology</i> , 2021, 12, 673487.	4.8	5
319	Immune-mediated bile duct injury: The case of primary biliary cirrhosis. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2010, 1, 118.	1.0	5
320	Somatostatin analogs in patients with Zollinger Ellison syndrome (ZES): an observational study. <i>Endocrine</i> , 2022, 75, 942-948.	2.3	5
321	An update on novel pharmacological agents for primary sclerosing cholangitis. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 69-77.	3.4	5
322	Role of X chromosome defects in primary biliary cirrhosis. <i>Hepatology Research</i> , 2007, 37, S384-S388.	3.4	4
323	X chromosome in autoimmune diseases. <i>Expert Review of Clinical Immunology</i> , 2008, 4, 591-597.	3.0	4
324	The X-factor in primary biliary cirrhosis: monosomy X and xenobiotics. <i>Autoimmunity Highlights</i> , 2012, 3, 127-132.	3.9	4

#	ARTICLE	IF	CITATIONS
325	Effects of Acute Carnosine and Î²-Alanine on Isometric Force and Jumping Performance. <i>International Journal of Sports Physiology and Performance</i> , 2016, 11, 344-349.	2.3	4
326	Treatment of <sc>PBC</sc>â€™A step forward. <i>Liver International</i> , 2017, 37, 503-505.	3.9	4
327	Editorial: liver transplantation for primary biliary cholangitisâ€™the need for timely and more effective treatments. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 472-473.	3.7	4
328	Antiâ€™gp210 and other antiâ€™nuclear pore complex autoantibodies in primary biliary cholangitis: What we know and what we should know. <i>Liver International</i> , 2021, 41, 432-435.	3.9	4
329	The mode of dexamethasone decoration influences avidin-nucleic-acid-nano-assembly organ biodistribution and in vivo drug persistence. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2022, 40, 102497.	3.3	4
330	Reply to: HultstrÃ¶m et al., Genetic determinants of mannose-binding lectin activity predispose to thromboembolic complications in critical COVID-19. <i>Mannose-binding lectin genetics in COVID-19. Nature Immunology</i> , 2022, 23, 865-867.	14.5	4
331	ANTINUCLEAR ANTIBODIES: GENERAL INTRODUCTION. , 2007, , 129-133.		3
332	Human Î²-Defensin 2 in Primary Sclerosing Cholangitis. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e80.	2.5	3
333	Female preponderance of primary biliary cholangitis is all about our understanding of its autoimmune nature. <i>Hepatology</i> , 2018, 67, 1210-1212.	7.3	3
334	Individualizing Care. <i>Clinics in Liver Disease</i> , 2018, 22, 545-561.	2.1	3
335	Letter to the Editor: Might Denosumab Fit in Primary Biliary Cholangitis Treatment?. <i>Hepatology</i> , 2020, 72, 359-360.	7.3	3
336	Cost of illness of Primary Biliary Cholangitis - a population-based study. <i>Digestive and Liver Disease</i> , 2020, 53, 1167-1170.	0.9	3
337	Genetics of Autoimmune Liver Diseases. , 2020, , 69-85.		3
338	Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature. <i>Immunotherapy</i> , 2021, , .	2.0	3
339	T-cell receptor polymorphism in primary biliary cirrhosis. <i>Annali Italiani Di Medicina Interna: Organo Ufficiale Della SocietÃ Italiana Di Medicina Interna</i> , 2003, 18, 149-53.	0.1	3
340	Hepatitis C virus infection and diabetes: a complex bidirectional relationship. <i>Diabetes Research and Clinical Practice</i> , 2022, , 109870.	2.8	3
341	Duodenal Gastric Metaplasia and Duodenal Neuroendocrine Neoplasms: More Than a Simple Coincidence?. <i>Journal of Clinical Medicine</i> , 2022, 11, 2658.	2.4	3
342	The Search for a Practical Approach to Emerging Diseases: The Case of Severe Acute Respiratory Syndrome (SARS). <i>Autoimmunity</i> , 2002, 9, 113-117.	0.6	2

#	ARTICLE	IF	CITATIONS
343	Cytokines in Liver Health and Disease. , 2007, , 83-93.		2
344	ANTIMITOCHONDRIAL ANTIBODIES. , 2007, , 473-477.		2
345	Serum Autoantibodies: From Identification to Clinical Relevance. Clinical and Developmental Immunology, 2013, 2013, 1-3.	3.3	2
346	Cytokines in the Liver. , 2017, , 75-96.		2
347	Pre-treatment risk stratification in primary biliary cholangitis: A predictive model to guide first-line combination therapy. Digestive and Liver Disease, 2018, 50, 21-22.	0.9	2
348	FRI-016-Validation of the PRESto machine learning algorithm for the prediction of disease progression in patients with primary sclerosing cholangitis. Journal of Hepatology, 2019, 70, e390-e391.	3.7	2
349	Additive beneficial effects of Fibrates combined with Obeticholic acid in the treatment of patients with Primary Biliary Cholangitis and inadequate response to second-line therapy: data from the Italian PBC Study Group. Digestive and Liver Disease, 2020, 52, e32.	0.9	2
350	The seat of life. What a lesson from the stigmatized saints. Liver International, 2021, 41, 1675-1676.	3.9	2
351	Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. Digestive and Liver Disease, 2021, 53, 1603-1609.	0.9	2
352	Open challenges in the management of autoimmune hepatitis. Minerva Gastroenterology, 2020, , .	0.5	2
353	Acute carnosine and \hat{I}^2 -alanine supplementation increase the compensated part of the ventilation versus work rate relationship during a ramp incremental cycle test in physically active men. Journal of Sports Medicine and Physical Fitness, 2020, 61, 37-43.	0.7	2
354	Simplified care-pathway selection for nonspecialist practice. European Journal of Gastroenterology and Hepatology, 2020, Publish Ahead of Print, .	1.6	2
355	Risk stratification in primary sclerosing cholangitis. Minerva Gastroenterology, 2020, , .	0.5	2
356	Hyperlipidemic state and cardiovascular risk in course of primary biliary cirrhosis. Gastroenterology, 2000, 118, A1008.	1.3	1
357	Lack of serum antibodies to membrane bound carbonic anhydrase IV in patients with primary biliary cirrhosis. Gut, 2005, 54, 1665-1665.	12.1	1
358	WHAT IS AN AUTOANTIBODY??. , 2007, , 3-6.		1
359	NUCLEAR ENVELOPE PROTEIN AUTOANTIBODIES/ANTILAMIN AUTOANTIBODIES. , 2007, , 191-196.		1
360	Primary sclerosing cholangitis is changing clinical spectrum and old biomarkers disclose an innovative role: The case of alkaline phosphatase. Digestive and Liver Disease, 2011, 43, 268-269.	0.9	1

#	ARTICLE	IF	CITATIONS
361	Sa1579 Durable Response in the Markers of Cholestasis through 18 Months of Open-Label Long Term Safety Extension Study of Obeticholic Acid in Primary Biliary Cirrhosis. <i>Gastroenterology</i> , 2016, 150, S1073-S1074.	1.3	1
362	Novel treatments targeting immune-related mechanisms in primary biliary cholangitis. <i>Clinical Liver Disease</i> , 2016, 8, 127-131.	2.1	1
363	Secretin-Stimulation of Bicarbonate Secretion Reduces Biliary Damage and Liver Fibrosis in a Model of Primary Biliary Cholangitis (PBC). <i>Gastroenterology</i> , 2017, 152, S1060.	1.3	1
364	Mo1470 " Secretin/Secretin Receptor Signaling Modulates Biliary Immunobiology and Subsequent T Cell Migration in Early Stage Primary Biliary Cholangitis (PBC). <i>Gastroenterology</i> , 2019, 156, S-1318.	1.3	1
365	FRI-046-Raising awareness and messaging risk in patients with primary biliary cholangitis: The rapid Global PBC Screening Test. <i>Journal of Hepatology</i> , 2019, 70, e404.	3.7	1
366	Comment on "Early Prognostic Utility of Gp210 Antibody-Positive Rate in Primary Biliary Cholangitis: A Meta-Analysis" <i>Disease Markers</i> , 2020, 2020, 1-2.	1.3	1
367	Primary Biliary Cirrhosis and Autoimmune Cholangitis. , 2007, , 235-247.		1
368	Validation of the Japanese version of the Fisk Fatigue Severity Score (FFSS) in Japanese patients with primary biliary cirrhosis. <i>Acta Hepatologica Japonica</i> , 2009, 50, 51-59.	0.1	1
369	Primary biliary cholangitis: perception and expectation of illness. <i>Digestive and Liver Disease</i> , 2022, 54, 1230-1233.	0.9	1
370	Conjugated bilirubin is an accurate marker of cholestasis in primary biliary cirrhosis. <i>Gastroenterology</i> , 2000, 118, A900.	1.3	0
371	Autoantibody Recognition of Functional Sites. , 2006, , 473-491.		0
372	Biliary insulin like growth factor-1 (IGF1) is a sensitive marker for the diagnosis of extrahepatic cholangiocarcinoma. <i>Digestive and Liver Disease</i> , 2007, 39, A5.	0.9	0
373	Identification of Serum and Tissue Micro-RNA Expression Profiles in Different Stages of the Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2011, 140, S-273.	1.3	0
374	Melatonin Inhibits In Vivo Cholangiocarcinoma Growth by Enhanced Biliary Expression of Serotonin N-Acetyltransferase (AANAT) the Key Enzyme Involved in Melatonin Synthesis. <i>Gastroenterology</i> , 2011, 140, S-910.	1.3	0
375	Hunting for fibrosis progression genes in hepatitis C patients. <i>Clinical Science</i> , 2011, 120, 285-286.	4.3	0
376	941 ALKALINE PHOSPHATASE VALUES ARE A SURROGATE MARKER IN PREDICTION OF TRANSPLANT FREE SURVIVAL IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS " AN INTERNATIONAL, COLLABORATIVE ANALYSIS. <i>Journal of Hepatology</i> , 2013, 58, S388.	3.7	0
377	OC-030...Effective Stratification Of Hepatocellular Carcinoma Risk In Primary Biliary Cirrhosis: Results Of A Multi-centre International Study. <i>Gut</i> , 2014, 63, A15-A16.	12.1	0
378	Nuclear Envelope Protein Autoantibodies/Antilamin Autoantibodies. , 2014, , 219-223.		0

#	ARTICLE	IF	CITATIONS
379	Smooth Muscle Autoantibodies. , 2014, , 491-495.		0
380	Stem cell niche and macrophages in human cholangiocarcinoma. Digestive and Liver Disease, 2014, 46, e4.	0.9	0
381	Infection and Autoimmune Liver Diseases. , 2015, , 839-857.		0
382	P1147 : Validation of an alkaline phosphatase and bilirubin response criterion as biomarker for transplant-free survival in primary biliary cirrhosis in the world's two largest cohorts. Journal of Hepatology, 2015, 62, S782-S783.	3.7	0
383	Sa1567 UDCA Treatment Reverses Biliary Proliferation and Hepatic Fibrosis in Mdr2 ^{-/-} Mice and Human PSC By Decreasing Mast Cell Infiltration and Histamine Release. Gastroenterology, 2016, 150, S1069.	1.3	0
384	Durable response in the markers of cholestasis through 24 months of open-label extension with obeticholic acid in Italian patients with primary biliary cholangitis. Digestive and Liver Disease, 2017, 49, e21.	0.9	0
385	Durable response in the markers of cholestasis through 36 months of open-label extension with obeticholic acid in Italian patients with primary biliary cholangitis. Digestive and Liver Disease, 2018, 50, 26.	0.9	0
386	Primary Biliary Cholangitis (PBC): The emotional perception of the disease journey from a patient's perspective. Digestive and Liver Disease, 2018, 50, 57.	0.9	0
387	The Epigenetics of Primary Biliary Cholangitis. , 2018, , 251-272.		0
388	Younger age is associated with lower transplant-free survival relative to a general population in patients with Primary Biliary Cholangitis. Journal of Hepatology, 2018, 68, S222-S223.	3.7	0
389	Stratification of hepatocellular carcinoma risk using the GLOBE score in patients with primary biliary cholangitis: the Global PBC Study Group. Journal of Hepatology, 2018, 68, S229-S230.	3.7	0
390	A dose-response relationship in the association between ursodeoxycholic acid treatment and prolonged transplant-free survival in primary biliary cholangitis. Journal of Hepatology, 2018, 68, S230.	3.7	0
391	FRI-021-Comparing the predictive performance of the Mayo risk score and the GLOBE score in a large cohort of patients with primary biliary cholangitis. Journal of Hepatology, 2019, 70, e392-e393.	3.7	0
392	THU-010-Shedding light on the X chromosome contribution to the genetic architecture of primary biliary cholangitis. Journal of Hepatology, 2019, 70, e165.	3.7	0
393	FRI-008-Incidence, prevalence and mortality of primary sclerosing cholangitis in Italy: A population-based study. Journal of Hepatology, 2019, 70, e386.	3.7	0
394	THU-128-Renal safety in 3,264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study. Journal of Hepatology, 2019, 70, e215-e216.	3.7	0
395	FRI-011-Ductular reaction, intermediate hepatocytes and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis. Journal of Hepatology, 2019, 70, e387-e388.	3.7	0
396	Ductular reaction, intermediate hepatocytes and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis. Digestive and Liver Disease, 2019, 51, e1.	0.9	0

#	ARTICLE	IF	CITATIONS
397	Individualizing Care. Surgical Oncology Clinics of North America, 2020, 29, 87-103.	1.5	0
398	Perception of illness in Italian patients with Primary Biliary Cholangitis referred to tertiary care units. Digestive and Liver Disease, 2020, 52, e6.	0.9	0
399	Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on alkaline phosphatase. Digestive and Liver Disease, 2020, 52, e4-e5.	0.9	0
400	Reply to: "A spotlight on natural killer cells in primary biliary cholangitis". Journal of Hepatology, 2021, 74, 255-256.	3.7	0
401	Identifying Racial Disparities in Primary Biliary Cholangitis Patients: A Step Toward Achieving Equitable Outcomes Among All. Digestive Diseases and Sciences, 2021, 66, 1386-1387.	2.3	0
402	Takayasu arteritis and primary sclerosing cholangitis: A casual association or different phenotypes of the same disease?. Journal of Translational Autoimmunity, 2021, 4, 100124.	4.0	0
403	Elastography in Autoimmune Liver Diseases. , 2021, , 91-103.		0
404	Old and novel prognostic biomarkers in primary biliary cholangitis. Expert Opinion on Orphan Drugs, 2021, 9, 123-131.	0.8	0
405	Combined ursodeoxycholic acid/secretin treatment reduces biliary senescence and liver fibrosis in a murine model of late stage primary biliary cholangitis. FASEB Journal, 2020, 34, 1-1.	0.5	0
406	PTU-46...Safety and efficacy of fully covered metallic stent placement for patients with primary sclerosing cholangitis. , 2021, , .		0
407	X marks the spot in autoimmunity. Expert Review of Clinical Immunology, 2022, 18, 429-437.	3.0	0